Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA）for breast cancer.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Fuda Cancer Hospital, Guangzhou
NCT06892093 · HER2-positive Breast Cancer, Diarrhea Caused by Drug, and more
NCT07310420 · Advanced Breast Cancer
NCT07586215 · Breast Cancer Metastatic
NCT05831878 · Advanced Breast Cancer
NCT06110793 · Metastatic Breast Cancer
Central laboratory in Fuda cancer hospital
Guangzhou, Guangdong
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions